5372912025-04-012025-06-305372912025-04-012025-06-30in-capmkt:OtherExpenses1Member5372912025-04-012025-06-30in-capmkt:OtherExpenses2Memberiso4217:INRiso4217:INRxbrli:shares537291NATHBIOGENNOTLISTEDINE448G01010NATH BIO-GENES (INDIA) LIMITEDMain BoardEquity2025-04-012026-03-312025-07-112025-07-04INRLakhsQuarterlyFirst quarterSingle segmentSEED CULTIVATION2025-07-1114:00:002025-07-1116:30:00Not applicable2025-04-012025-06-30UnauditedConsolidated28370010001764500028546460001088518000435330002661880009592700031961000975000095999600024958730003587730002063400037940700065970000659700003728100000000372810000-80000037201000000001900400001019.5819.580019.5819.58Notes <BR> <BR> 1. The consolidated financial results were reviewed by the Audit Committee in meeting held on 10th July 2025 and were thereafter apprved by the Board of Directors at its meeting held on 11th July 2025. <BR> <BR> 2. The Company is dealing in one major segment. i.e. Seeds Cultivation. <BR> <BR> 3. The results have been consolidated with Nath Bio-Genes CA, Uzbekistan where in the Company is holding 90% of Equity. <BR> <BR> 4. Investor Complaints Opening Balance- 0, Received and solved- 0, closing balance-0. <BR> <BR> 5. The figures have been regrouped/ rearranged where ever necessary. <BR> <BR> Selling and Distribution Expenses866991000Other Expenditure930050000800000-800000